» Articles » PMID: 30092946

Coronary Microvascular Dysfunction and Cardiovascular Risk in Obese Patients

Abstract

Background: Besides body mass index (BMI), other discriminators of cardiovascular risk are needed in obese patients, who may or may not undergo consideration for bariatric surgery. Coronary microvascular dysfunction (CMD), defined as impaired coronary flow reserve (CFR) in the absence of flow-limiting coronary artery disease, identifies patients at risk for adverse events independently of traditional risk factors.

Objectives: The study sought to investigate the relationship among obesity, CMD, and adverse outcomes.

Methods: Consecutive patients undergoing evaluation for coronary artery disease with cardiac stress positron emission tomography demonstrating normal perfusion (N = 827) were followed for median 5.6 years for events, including death and hospitalization for myocardial infarction or heart failure.

Results: An inverted independent J-shaped relationship was observed between BMI and CFR, such that in obese patients CFR decreased linearly with increasing BMI (adjusted p < 0.0001). In adjusted analyses, CFR but not BMI remained independently associated with events (for a 1-U decrease in CFR, adjusted hazard ratio: 1.95; 95% confidence interval: 1.41 to 2.69; p < 0.001; for a 10-U increase in BMI, adjusted hazard ratio: 1.20; 95% confidence interval: 0.95 to 1.50; p = 0.125) and improved model discrimination (C-index 0.71 to 0.74). In obese patients, individuals with impaired CFR demonstrated a higher adjusted rate of events (5.7% vs. 2.6%; p = 0.002), even in those not currently meeting indications for bariatric surgery (6.4% vs. 2.6%; p = 0.04).

Conclusions: In patients referred for testing, CMD was independently associated with elevated BMI and adverse outcomes, and was a better discriminator of risk than BMI and traditional risk factors. CFR may facilitate management of obese patients beyond currently used markers of risk.

Citing Articles

Myocardial blood flow reference values for 13N-ammonia PET myocardial perfusion imaging in patients without flow-limiting coronary artery disease.

Pingree R, Markendorf S, Moysidis D, Ryffel C, Stuetz M, Ghenzi R Eur J Nucl Med Mol Imaging. 2025; .

PMID: 40082264 DOI: 10.1007/s00259-025-07196-0.


Impact of physiological and coronary artery disease risk factors on myocardial perfusion in stress computed tomography myocardial perfusion imaging.

Kong W, Shang L, Long B, Chen X, Mou A, Pu H Sci Rep. 2025; 15(1):4967.

PMID: 39929941 PMC: 11811010. DOI: 10.1038/s41598-025-88836-1.


Value of cardiac enzyme spectrum for the risk assessment of mortality in critically ill children: a single-centre retrospective study.

Wang H, Chen X, Shen C, Wang J, Chen C, Huang J BMJ Open. 2024; 14(10):e074672.

PMID: 39414301 PMC: 11487822. DOI: 10.1136/bmjopen-2023-074672.


Patients With Nonobstructive Coronary Artery Disease and Chest Pain: Impact of Obesity and Depressive Symptoms.

Vatsa N, Dave E, Higgins M, Huang J, Desai S, Gold D J Am Heart Assoc. 2024; 13(19):e031429.

PMID: 39344631 PMC: 11681450. DOI: 10.1161/JAHA.123.031429.


Higher fasting glucose is associated with poorer survival in non-diabetic subjects having ischemia with non-obstructive coronary arteries.

Liang K, Sheu W, Lee W, Wang J, Lee W Sci Rep. 2024; 14(1):20681.

PMID: 39237714 PMC: 11377422. DOI: 10.1038/s41598-024-71796-3.


References
1.
Pareek M, Schauer P, Kaplan L, Leiter L, Rubino F, Bhatt D . Metabolic Surgery: Weight Loss, Diabetes, and Beyond. J Am Coll Cardiol. 2018; 71(6):670-687. DOI: 10.1016/j.jacc.2017.12.014. View

2.
Taqueti V, Dorbala S, Wolinsky D, Abbott B, Heller G, Bateman T . Myocardial perfusion imaging in women for the evaluation of stable ischemic heart disease-state-of-the-evidence and clinical recommendations. J Nucl Cardiol. 2017; 24(4):1402-1426. PMC: 5942593. DOI: 10.1007/s12350-017-0926-8. View

3.
Taqueti V, Solomon S, Shah A, Desai A, Groarke J, Osborne M . Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J. 2018; 39(10):840-849. PMC: 5939665. DOI: 10.1093/eurheartj/ehx721. View

4.
Chow B, Dorbala S, Di Carli M, Merhige M, Williams B, Veledar E . Prognostic value of PET myocardial perfusion imaging in obese patients. JACC Cardiovasc Imaging. 2014; 7(3):278-87. DOI: 10.1016/j.jcmg.2013.12.008. View

5.
Harnett D, Hazra S, Maze R, Mc Ardle B, Alenazy A, Simard T . Clinical performance of Rb-82 myocardial perfusion PET and Tc-99m-based SPECT in patients with extreme obesity. J Nucl Cardiol. 2017; 26(1):275-283. DOI: 10.1007/s12350-017-0855-6. View